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Abstract
Introduction: Obesity is associated with a number of diseases resulting from the excessive amount of adipose tissue. The aim of this study
was to investigate the correlation between the quantity of adipose tissue and the prevalence of metabolic disturbances, and the concentra-
tion of adipokines and proinflammatory cytokines in obese or overweight patients.
Material and methods: Fifty-five middle-aged subjects with body mass index (BMI) > 25 kg/m2 took part in this study. Twenty-three
healthy people with normal BMI formed the control group. Twenty-one people from the study group were on a low-calorie diet. All
subjects underwent anthropometric assessment, laboratory investigations, and blood-pressure examination.
Results: Patients with obesity or overweight, in comparison to those with normal BMI, showed insulin resistance and a higher concentra-
tion of high sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor 1 (PAI-1), and interleukin 6 (Il-6). The concentration of
adiponectin was significantly lower in this group.
The patients on the low-calorie diet had significantly lower concentrations of leptin when compared to other obese people; moreover,
a trend towards decreased hs-CRP concentration was seen.
A significant positive correlation between leptin and hs-CRP was observed. The serum concentration of adiponectin was inversely corre-
lated with that of TNF-a, IL-6, hs-CRP, and PAI-1.
Conclusions: The results of this study may suggest the beneficial impact of a low-calorie diet on the slowing down of inflammatory
processes. The observed negative correlation between the concentrations of adiponectin and inflammatory cytokines may confirm the
anti-inflammatory activity of this adipokine. (Pol J Endocrinol 2010; 61 (2): 160–168)
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Streszczenie
Wstęp: Otyłość wiąże się z nadmiernym gromadzeniem tkanki tłuszczowej i w konsekwencji prowadzi do wielu poważnych stanów
chorobowych. Celem pracy było zbadanie związku pomiędzy ilością tkanki tłuszczowej a występowaniem powikłań metabolicznych,
stężeniem adipokin oraz cytokin prozapalnych u osób z nadwagą lub otyłością.
Materiał i metody: W badaniu wzięło udział 55 osób w średnim wieku ze wskaźnikiem masy ciała (BMI, body mass index) poniżej 25 kg/m2.
Grupę kontrolną stanowiły 23 zdrowe osoby z BMI w granicach normy. Dietę niskokaloryczną stosowało 21 osób spośród grupy badanej.
U wszystkich osób wykonano pomiary antropometryczne, badania biochemiczne oraz pomiar ciśnienia tętniczego.
Wyniki: U pacjentów z nadwagą lub otyłością stwierdzono cechy insulinooporności, podwyższone stężenia wysoko czułego białka
C-reaktywnego (hs-CRP, high sensitivity C-reactive protein), inhibitora aktywatora plasminogenu 1 (PAI-1, plasminogen activator inhibitor 1)
oraz interleukiny 6 (IL-6, interleukin 6) w porównaniu z osobami z prawidłową masą ciała. Stężenie adiponektyny było znacząco niższe w
grupie z nadwagą i otyłością.
Otyli pacjenci stosujący dietę niskokaloryczną mieli znacząco niższe stężenia leptyny oraz wykazywali tendencję do niższych wartości hs-CRP,
w porównaniu z pozostałymi osobami z nadwagą lub otyłością. W badanu stwierdzono dodatnią korelację pomiędzy stężeniem leptyny
i hs-CRP, natomiast stężenie adiponektyny ujemnie korelowało z TNF-a, IL-6, hs-CRP oraz PAI-1.
Wnioski: Uzyskane wyniki sugerują pozytywny wpływ zastosowania diety niskokalorycznej na zmniejszenie przewlekłego stanu zapal-
nego u osób z nadwagą czy otyłością. Obserwowana ujemna korelacja pomiędzy adiponektyną a cytokinami prozaplanymi potwierdza
jej przeciwzapalane właściwości.
(Endokrynol Pol 2010; 61 (2): 160–168)
Słowa kluczowe: otyłość, adipokiny, stan zapalny
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Introduction
Obesity is a chronic disease that concerns over a billion
adult people throughout the world. It is estimated that
the number of those affected by the disease will double
by the year 2030. Consequently, we can talk about an
obesity epidemic which is going to become the biggest
health problem of our century. What is more, along with
the number of those suffering from obesity, the preva-
lence of complications resulting from the excess of adi-
pose tissue is also growing [1–3]
Adipose tissue is the biggest energy reservoir of the
organism. The main function of adipose tissue is synthe-
sis and storage of triglycerides in the period of positive
energy balance. It is involved in the mobilization of stored
energy in the period of negative energy balance.
Adipose tissue plays a role as a mechanical shield
for tissues lying in deeper parts as well as a thermal
isolator [4–6].
Moreover, adipose tissue is the location of synthesis
of numerous, metabolically active proteins, the so-called
adipokines. These proteins play an important role in
the regulation of local and systemic metabolism, show-
ing typical endocrine activity. That is to say, adipose
tissue is a significant element of the endocrine system
in humans [4, 6–8].
Adipokines are responsible for the interactions be-
tween adipose tissue, muscular tissue, adrenal cortex,
and the central and sympathetic nervous system. They
take part in maintaining energetic balance, and they have
an influence on insulin sensitivity, blood pressure regula-
tion, immunological processes, angiogenesis, fat metabo-
lism, and haemostasis [4, 8–11]. Ghrelin, the only orexi-
genic peptide produced by the digestive tract, is reduced
in obesity. Together with adipokines, ghrelin modulates
appetite and energy balance in obese patients [12].
Adipose tissue is the place of synthesis for many
proteins involved in inflammatory processes. Cytokines
connected with inflammation and secreted by adipocyte
include, among others, TNF-a, numerous interleukins
(IL-1b, IL-6, IL-8, IL-10), plasminogen activator inhibi-
tor 1 (PAI-1), monocyte chemotactic protein 1 (MCP-1),
and macrophage migration inhibitory factor (MIF) [13].
Adipokines such as leptin, resistin, Vascular Endot-
helial Growth Factor (VEGF), and Nerve Growth Fac-
tor (NGF) are also related to the development of inflam-
mation. The concentration of most pro-inflammatory
cytokines (which are produced more by macrophages
than by adipocytes) increases along with the growth of
fat body mass.
Therefore, obesity may be characterized by a co-ex-
isting chronic inflammatory state. A positive correlation
between the body mass index (BMI) and CRP values
has been described. Increased CRP levels are observed
in patients with metabolic syndrome and insulin resis-
tance [14]. In addition, CRP concentration negatively
correlates with adiponectin levels. Chronic inflamma-
tion may play a leading role in the development of in-
sulin resistance and metabolic syndrome [6, 9, 15–17].
Thus, obesity is related to disordered, inadequate
immune reaction and higher risk of diseases such as
diabetes and atherosclerosis.
Balanced nutrition is the only way of maintaining
proper function of the immune system. The ongoing
inflammatory process in adipose tissue is similar in
mechanism to the inflammatory reaction present in
malignant and autoimmune diseases [18].
Nowadays it is assumed that unfavourable changes
in secretion of adipose tissue hormones and inflamma-
tory cytokines caused by obesity have an influence the
development of metabolic syndrome and vascular com-
plications. Since the discovery of leptin and the other
adipokines, studies on the aetiology of diseases related
to obesity have been aimed at the understanding of
metabolic and endocrine functions of the adipose tis-
sue [11, 17].
The aim of this study was to investigate the correla-
tion between the amount of adipose tissue and the prev-
alence of metabolic disturbances as well as the concen-
trations of adipokines and proinflammatory cytokines
in obese or overweight patients.
Material and methods
The study was performed in a group of 55 patients with
obesity or overweight (called the overweight group).
The group was made up of adult subjects (38 women
and 17 men) with BMI over 25 kg/m2. All patients were
stable, without clinical signs of acute inflammation.
They started treatment in the Out-Patients’ Ambu-
latory of the Clinical Nutrition Department of the Med-
ical University of Gdansk. The basic criteria of inclu-
sion to the study were:
— BMI > 25 kg/m2;
— age > 18 years
The patients were interviewed regading their life-
style and diet. No specific standard diet was given to
the patients in this study, with the exception 21 patients
on a low-calorie diet for one month. In the group of
21 patients, 10 had moderate physical activity. They
were introduced to an exercise program of 1 hour of
jogging twice a week in a gymnasium.
Patients thought to have secondary obesity as judged
by interviews and examinations were excluded from the
study. Also, women taking oral contraceptives or hormonal
replacement therapy, within six months of giving birth or
breastfeeding, and patients with endocrine, mental, ma-
lignant, or serious medical diseases were excluded.
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The control group consisted of 23 healthy people
(volunteers) with BMI below 25 kg/m2 (17 women and
6 men).
The patients underwent anthropometric measure-
ments, laboratory investigations, and blood-pressure
examination.
The protocols were approved by the Local Ethics
Committee, and informed consent was obtained from
each patient.
Anthropometric measurements
The following measurements were determined:
— body mass (kg), waist circumference (cm), hip cir-
cumference (cm);
— BMI — was calculated as the ratio of the current body
mass/height2 [kg/m2]. BMI values in the range of
25–30 kg/m2 were termed overweight, BMI ≥ 30 kg/m2
was called obesity [3];
— WHR — estimated based on waist to hip circumfer-
ences ratio;
— body composition: the body fat content (%F) and
lean body mass (LBM) were obtained by near- in-
frared spectroscopy method (NIR) using a Futrex
5000A unit (Gatesburg Inc., USA).
Body mass and height were measured with attested
electronic scales and a body-height measuring device.
Laboratory assay
Blood samples were collected after an overnight fast of
12 hours and the levels of the following compounds
were measured in serum:
— Glucose by enzymatic-calorimetric method,
EMAPOL;
— Insulin by MEIA method (microparticle enzyme im-
munoassay), using units and IMX by Abbott, USA;
— Leptin by ELISA method, DRG Germany units and
read on STAT FAX 2200, USA;
— Adiponectin by ELISA method, Linco (USA);
— Resistin by ELISA method, Linco (USA);
— TNF-alpha by ELISA method, Bender MedSystem
(Austria);
— hs-CRP DRG (Germany);
— IL-6 Bender MedSystem (Austria);
— PAI-1 by ELISA method, Roche (France);
— total cholesterol (TC), triglycerides (TG), HDL-choles-
terol (HDL) by routine methods using a Hitachi 911.
Insulin-resistance HOMA1-IR index was calculated
according to the following formula: fasting insulin lev-
el (mU/L) × fasting glucose level (mmol/L) / 22.5.
Blood pressure was checked twice: sitting and af-
ter at least 15 minutes’ rest using a proper sleeve. In
this study an average from the two measurements is
given.
Statistical analysis
The data are expressed as means ± SD (statistical devi-
ation). Significant differences were defined as p < 0.05.
The correlations and significance were evaluated with
nonparametric statistics. Logistic regression method was
also used (using “Statistica version 7.1”; StatSoft, Pols-
ka, Kraków, 2005).
Results
The characteristics of the studied groups are shown in
Table I. The mean age of the patients was 38.8 ± 10.2 yea-
rs in the overweight group and 36.3 ± 9.1 years in the
control group. There was no significant difference in
the age and sex of subjects between the control and
overweight groups. Among the investigated popula-
tion, 21 patients were on a low-calorie (LC) diet (1200–
–1800 kcal/daily), and 10 of these patients took part in
physical activities at the same time.
In the study group, six people (10.9%) were treated
for high blood pressure. Moreover, five patients in the
study group had abnormal fasting glucose levels (treat-
ed non pharmacologically). None of the patients was
treated for dyslipidaemia.
In the study group, the mean BMI was 33.8 kg/m2,
mean%F — 41%, and waist circumference — 107.9 cm.
In the control group, the mean BMI was 22.2 kg/m2,%F
— 26.3%, and waist circumference 76.9 cm.
Both groups differed in all studied anthropometri-
cal parameters with the exception of height. Addition-
ally, SBP (systolic blood pressure) and DBP (diastolic
blood pressure) were significantly higher in the over-
weight group when compared to the control group (see
Table I).
Insulin resistance levels in both groups are shown
in Table I.
In the overweight group the mean concentration of
insulin was higher than in the control group (22.8 ±
± 17.2 µIU/mL v. 10.1 ± 2.9 µIU/mL).
In the overweight group a wide dispersion of re-
sults was observed: the range of insulin concentration
was between 5.5 and 89.0 µIU/mL.
Mean value of HOMA index in the overweight
group was 5.2 ± 4 compared to 2.4 ± 0.7 in the controls.
The differences in the parameters of insulin resistance
were statistically significant (see Table I).
Mean concentrations of fasting glucose in the over-
weight group and control group were similar. Both
groups differed with regard to all lipid parameters.
What is more, there were statistically significant dif-
ferences in the mean concentrations of hs-CRP and PAI-1
(see Table II). The positive correlation between hs-CRP
and BMI are shown in Figure 1.
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The mean concentration of adiponectin in the over-
weight group was 16.7 µg/mL and IL-6 level was 3.0 pg/
/mL. In the control group, the mean concentration of
adiponectin was higher (24.2 µg/mL), while IL-6 was
lower (2.5 pg/mL). The differences were statistically sig-
nificant (Table II, Fig. 2).
The difference between the mean levels of resistin,
TNF-a, and leptin in both studied groups was not statis-
tically significant. However, the concentration of leptin
in the overweight group was almost 20%, and TNF-a
was about 15% higher in comparison to the controls
(Table II).
The univariate analysis demonstrated a significant
negative correlation between the concentrations of adi-
ponectin and BMI, WHR, waist circumference, %F, in-
sulin concentration, and HOMA-IR values (see Table III).
Adiponectin correlated positively with HDL-cholester-
ol, negatively with LDL–cholesterol, and negatively
with the concentration of triglycerides (see Table IV).
Moreover, adiponectin showed a negative correlation
with TNF-a, IL-6, hs-CRP, and PAI-1 (see Table V).
Table I. The anthropometric measurements, SBP, DBP, and
markers of insulin resistance in both studied groups
Tabela I. Pomiary antropometryczne, skurczowe ciśnienie
tętnicze, rozkurczowe ciśniene tętnicze i markery insulino-
oporności w obu grupach badanych
Parameters Overweight Control p
(n = 55) (n = 23)
F/M 38/17 17/6 ns
Age (years)
Mean ± SD 38.8 ± 10.2 36.3 ± 9.10 ns
Range 19–59 28–55
Height [cm]
Mean ± SD 168.7 ± 9.9 168.8 ± 7.2 ns
Range 152–200 155–185
Body weight [kg]
Mean ± SD 96.6 ± 21.2 63.2 ± 7.8 < 0.001
Range 65.5–150 48.5–78
BMI [kg/m2]
Mean ± SD 33.8 ± 6.1 22.2 ± 1.9 < 0.001
Range 26–50.7 18.6–24.7
Waist circumference [cm]
Mean ± SD 107.9 ± 15.2 76.9 ± 6.9 < 0.001
Range 88–165 64–93
Hip circumference [cm]
Mean ± SD 105 ± 10.4 97.3 ± 5.9 < 0.001
Range 91–150 88–109
WHR
Mean ± SD 0.94 ± 0.08 0.79 ± 0.07 < 0.001
Range 0.8–1.14 0.7–0.93
Body fat (%)
Mean ± SD 41.5 ± 7.4 26.3 ± 5.0 < 0.001
Range 25–60 16.8–34.5
Body fat [kg]
Mean ± SD 40.8 ± 14.1 16.7 ± 3.8 < 0.001
Range 21.2–80.7 9.4–22.8
SBP [mm Hg]
Mean ± SD 128.3 ± 17.8 101.7 ± 10.4 < 0.001
Range 100–170 90–127.5
DBP [mm Hg]
Mean ± SD 81.1 ± 12.2 67.3 ± 6.9 < 0.001
Range 60–100 60–80
Insulin [ìIU/mL]
Mean ± SD 22.8 ± 17.2 10.1 ± 2.9 < 0.001
Range 5.5–89 6.8–17.2
HOMA
Mean ± SD 5.2 ± 4.0 2.4 ± 0.74 < 0.001
Range 1.0–21.3 1.2–3.9
Glucose [mg/dL]
Mean ± SD 90.7 ± 10.8 86.6 ± 8.8 ns
Range 74–133 69.6–98
Table II. The biochemical parameters in both studied groups
Tabela II. Parametry biochemiczne w obu badanych grupach
Parameter Overweight Control p
(n = 55) (n = 23)
hs-CRP [mg/L]
Mean ± SD 7.9 ± 3.9 4.8 ± 3.4 0.002
Range 1.0–10.65 1.2–13.3
PAI-1 [ng/mL]*
Mean ± SD 61.9 ± 30.2 21.8 ± 13.4 < 0.001
Range 21.2–145.2 5.9–56.7
Total cholesterol
[mg/dL]
Mean ± SD 220.7 ± 50.6 196.3 ± 35.2 0.04
Range 152–452 131–273
LDL [mg/dL]
Mean ± SD 140.6 ± 44.8 109.2 ± 29.7 0.04
Range 66.1–358.6 53–187.2
HDL [mg/dL]
Mean ± SD 45.3 ± 10.1 57.4 ± 17.4 0.003
Range 27.4–70 30.8–99.4
Triglycerides [mg/dL]
Mean ± SD 170.8 ± 95.3 99 ± 45.7 < 0.001
Range 37–457 52–225
Adiponectin [ìg/mL]
Mean ± SD 16.7 ± 9.1 24.2 ± 8.6 < 0.001
Range 3.1–46.7 12–49.1
Resistin [ng/mL]
Mean ± SD 25 ± 16.2 23.2 ± 15.4 ns
Range 2.2–70.5 9.2–83.8
Leptin [ng/mL]
Mean ± SD 8.1 ± 10.7 6.6 ± 10.9 ns
Range 0.5–40.5 0.5–38.5
TNF-a [pg/mL]
Mean ± SD 16.7 ± 10.7 14.3 ± 8.6 ns
Range 5–66 4–32
Interleukin 6 [pg/mL]
Mean ± SD 3.0 ± 0.8 2.5 ± 0.4 0.03
Range 1.8–6.0 1.6–3.4
*for PAI-1 in the obese group : n = 25, in the control group n = 15
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Concentrations of other adipokines were not statis-
tically significantly affected by the LC diet. Adiponec-
tin concentrations in woman were significantly higher
than in men (21.3 ± 9.7 v. 13 ± 6.2 µg/mL (p < 0.001),
respectively). No significant difference in the concen-
tration of resistin and leptin was observed between the
two genders.
Discussion
Patients in the overweight group had levels of insulin
and insulin resistance two-times higher compared with
the controls. Hyperinsulinaemia and increased insulin
resistance, as demonstrated by HOMA index, in per-
sons with an excessive amount of adipose tissue were
confirmed in numerous observations [19–27].
Blum et al. [28] observed differences in HOMA in-
dex value even in a small studied group with moderate
obesity. Insulin resistance is a problem of obese people,
which increases with the age of studied patients [29].
Our study population was significantly different
from the control group with regard to all lipid parame-
ters. Hyperinsulinaemia and lowered concentration of
HDL-cholesterol co-existing with obesity have been
described many times [20, 21, 25, 30].
As demonstrated by others authors, the concentra-
tion of leptin in obese subjects is higher compared to
subjects with normal weight and shows a positive cor-
relation with BMI and WHR [22, 31, 32].
In our study there was no significant difference be-
tween leptin concentrations in the overweight group
in comparison to the control group. However, there was
a significant difference between leptin levels in obese
people on the LC diet and the other obese subjects. The
participants of the overweight group who were on the
LC diet had almost 14-times lower mean leptin concen-
tration when compared to other obese patients. We
supposed that the lack of significant differences in mean
leptin levels in the overweight and control groups was
the result of the LC diet used by 23 patients. Even
a short period of low food intake significantly lowers
leptin concentrations, disproportionately to body
weight reduction [33]. Other investigators noted a sig-
nificant decrease in the concentration of leptin after just
a 24-hour period of starvation, or a decrease of 72% af-
ter just 24 hours of calorie restriction [34, 35]. The above
results suggest that leptin secretion is also dependent
on other factors, not only on the content of body weight
or body fat [34].
During reduction of body weight, leptin concentra-
tion is significantly lower when compared to during
a stable period, and what is more, the effect is not depen-
dent on initial body weight or body composition [36]. The
described changes in leptin concentration suggest
Figure 2. The mean levels of adiponectin in relation to BMI.
** p £ 0.01
Rycina 2. Średnie stężenie adiponektyny w zależności od BMI.
** p £ 0,001
Figure 1. Mean plasma levels of hs-CRP in relation to BMI.
***p £ 0.001
Rycina 1. Średnie stężenie hs-CRP w osoczu w zależności od BMI.
***p £ 0,001
A significant negative correlation was also observed
between adiponectin and SBP as well as DBP (p < 0.001
for both variables).
Leptin concentration correlated positively with hs-
CRP (see Table V).
Patients on the LC diet
Patients on the LC diet presented a significantly lower
mean leptin concentration when compared to other obese
people (0.9 mg/mL v. 12.5 mg/mL, p < 0.001) (Fig. 3).
What is more, hs-CRP concentration was lower in
patients on LC diet than in other patients (6.2 mg/L v.
8.6 mg/L). This difference was close to being of statisti-
cal significance (p = 0.08).
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Table III. Correlations between studied parameters in overweight group in univariate analysis
Tabela III. Korelacja między badanymi parametrami w grupie pacjentów z nadwagą w analizie jednozmiennowej
Insulin HOMA WHR Waist F (%) F [kg] BMI [kg/m2]
[ìIU/mL] circumference
[cm]
Adiponectin –0.49*** –0.47*** –0.55*** –0.43*** –0.13 –0.29** –0.35***
Resistin –0.10 –0.09 –0.19 0.03 0.10 0.14 0.10
Leptin –0.01 –0.01 –0.02 0.13 0.12 0.17 0.20
TNF-a 0.10 0.12 0.16 0.10 –0.06 0.02 0.06
Interleukin 6 0.19 0.19 0.28* 0.38*** 0.31*** 0.34*** 0.36***
hs-CRP 0.5*** 0.48*** 0.09 0.35** 0.41*** 0.46*** 0.49***
PAI-1 0.59*** 0.63*** 0.52** 0.53*** 0.51*** 0.54*** 0.59***
Cortisol 0.32** 0.32*** 0.08 0.26* 0.33*** 0.32*** 0.35***
Total Cholesterol 0.05 0.07 0.17 0.18 0.29** 0.23* 0.24*
LDL-Cholesterol 0.12 0.13 0.2 0.23* 0.33*** 0.28** 0.29**
HDL-Cholesterol –0.41*** –0.40*** –0.48*** –0.44*** –0.22* –0.35*** –0.40***
Triglycerides 0.22 0.23* 0.47*** 0.44*** 0.35*** 0.39*** 0.41***
Insulin [mIU/mL] – – 0.35*** 0.51*** 0.40*** 0.54*** 0.56***
HOMA – – 0.35*** 0.53*** 0.39*** 0.55*** 0.56***
*p £ 0.05; **p £ 0.01; ***p £ 0.001
Table V. Correlations between studied adipokines in over-
weight group in univariate analysis
Tabela V. Korelacja między badanymi adipokinami u pa-
cjentów z nadwagą w analizie jednozmiennowej
Adiponectin Resistin Leptin TNF-a IL-6
Resistin 0.31** – – – –
Leptin 0.08 0.14 – – –
TNF-a –0.24* –0.15 0.09 – –
IL-6 –0.23* 0.05 0.07 0.16 –
hs-CRP –0.23* 0.18 0.22* –0.15 0.16
PAI-1 –0.54*** –0.01 –0.20 0.17 0.40**
*p £ 0.05; **p £ 0.01; ***p £ 0.001
Table IV. Correlations between studied biochemical parameters in overweight group in univariate analysis
Tabela IV. Korelacja między badanymi parametrami biochemicznymi w grupie pacjentów z nadwaga w analizie jedno-
zmiennowej
Total cholesterol LDL-cholesterol HDL-cholesterol Triglycerides
Adiponectin –0.10 –0.08 0.48*** –0.41***
Resistin –0.09 –0.01 0.13 –0.23*
Leptin –0.03 0.00 –0.05 0.01
TNF-a –0.03 –0.03 –0.19 0.15
IL-6 –0.09 0.06 –0.34*** 0.09
hs-CRP 0.05 0.15 –0.200 0.06
PAI-1 0.32* 0.40** –0.50*** 0.46***
*p £ 0.05; **p £ 0.01; ***p £ 0.001
Figure 3. The plasma leptin levels in relation to diet in the
overweight group. *** p £ 0.001
Rycina 3. Osoczowe stężenie leptyny w zależności od diety
w grupie z nadwagą ***p £ 0,001
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that leptin is a sensitive marker of current energy pro-
cesses [37, 38].
The regulation of leptin gene expression is highly
complex as it involves multiple mediators the relative
importance of which is, as yet, undetermined. The im-
portant regulatory factors are glucocorticoids, insulin,
and thyroid hormones. Thyroid hormones inhibit lep-
tin gene expression, and sex steroids such as oestrogen
increase leptin mRNA levels. Usually females have sig-
nificantly higher leptin levels than males [39], this sex-
ual dimorphism was not observed in our study. In our
overweight group, the mean age of males was higher
than that of the females, and the group of males (< 30%
of all studied patients) was relatively small.
The lack of difference in mean leptin concentrations
which we observed may also be the result of higher
energy expenditure in the studied group. It has been
observed that leptin concentrations could be modified
by physical activity, regardless of body weight [40, 41].
Some authors have shown that moderate physical ac-
tivity may support metabolism regulation by decreas-
ing concentrations of leptin and leptin resistance, de-
spite a lack of noticeable change in BMI.
In our study, there was no significant difference of
serum resistin and TNF concentrations in the over-
weight group in comparison to the control group. The
previous studies concerning the role of resistin in obe-
sity and insulin resistance were ambiguous. Only a few
authors indicated increased resistin concentration or
expression of mRNA for resistin in obesity. They pre-
sented decreased expression of mRNA for resistin in
adipose tissue in obese animals. In addition, in several
studies in obese humans there was no visible relation
between obesity and resistin level [42].
In obesity and hyperinsulinaemia status, increased
expression of mRNA for TNF in adipose tissue was ob-
served [8]. Some previous studies, although not all,
showed a positive correlation between expression
mRNA in adipose tissue and serum concentration of
TNF-a [43].
In the overweight group there a positive correlation
between hs-CRP and leptin concentration was ob-
served. This observation confirmed the pro-inflamma-
tory activity of leptin described in literature [16]. Thus,
it may be assumed that in obese people (as a result of
leptin resistance) there exists a lack of leptin anorexi-
genic activity. However, there was pro-inflammatory
activity of leptin. As we have shown, being on a LC diet
allows a significant decrease in leptin concentration. In
addition, there was a visible tendency towards lowered
hs-CRP concentration on the LC diet. Aksungar et al.
[44] also noticed a positive influence of the LC diet on
such markers of chronic inflammation as hs-CRP. The
reduction in leptin and hs-CRP concentrations is high-
er in the case of a low-carbohydrate diet than of a low-
fat diet [45].
Adiponectin is the main product of adipose tissue.
An increase in body fat content results in a decrease in
adiponectin serum concentration. In our study, over-
weight subjects had about 1.5-times lower concentra-
tions of this adipokine, which has anti-inflammatory
and anti-sclerotic effects. In our study, similarly to stud-
ies of other authors [46–52], in the overweight group
adiponectin concentration decreased along with in-
creased BMI, WHR,%F, and waist circumference. Also,
adiponectin levels decreased along with increased in-
sulin and HOMA index value. Adiponectin concentra-
tions were significantly higher in women [31, 48]. In
the overweight group, concentrations of adiponectin
correlated positively with HDL-cholesterol and nega-
tively with triglycerides. However, there was no corre-
lation between adiponectin and total cholesterol or LDL
fraction.
We observed a negative correlation of adiponectin
with SBP and DBP. Thus, along with a lowering of ad-
iponectin concentration, lipid abnormalities typical for
the metabolic syndrome as well as higher blood pres-
sure were observed. Such results confirm the correla-
tion between hypoadiponectinaemia and metabolic
syndrome [31, 52].
The adiponectin in the overweight group showed
a negative correlation with concentrations of pro-inflam-
matory cytokines IL-6 and TNF-a. Brunn et al. present-
ed data about the influence of this cytokine on adiponec-
tin secretion. They incubated a piece of subcutaneous
adipose tissue with IL-6 + IL6-R and with TNF-a. The
addition of such cytokines resulted in lowering of
mRNA for adiponectin [26]. Other authors also observed
lower expression of mRNA for adiponectin while, at the
same time, TNF-a in adipose tissue was increasing [49].
TNF-a, which is mostly synthesized by adipose tis-
sue macrophages, inhibits adiponectin transcription in
adipocytes. Therefore, it may be supposed that the in-
flammatory process in adipose tissue areas, which is
connected with obesity, is a cause of decreased concen-
tration of adiponectin in obese people [16].
In our study, adiponectin levels negatively correlat-
ed to concentrations of hs-CRP and PAI-1. This possi-
bly suggests the anti-inflammatory and anti-coagulant
activity of adiponectin [46, 47, 53, 54].
hs-CRP, as well as PAI-1, were significantly higher
in the overweight group when compared to control
group, similarly to other studies [20, 18, 22, 39]. In our
studied population, concentrations of hs-CRP increased
along with levels of obesity and insulin resistance. The
higher concentrations of IL-6 and hs-CRP which we ob-
served in the overweight group, as well as the positive
correlation between inflammatory cytokines and %F,
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may confirm the hypothesis that obesity is connected
to subclinical, chronic inflammation. The inflammato-
ry process co-existing with obesity is, among others, the
result of infiltration of adipose tissue by macrophages.
They may form up to 50% of cells of adipose tissue. Their
number grows along with accumulation of adipose tis-
sue and size of adipocytes. Adipose tissue macrophag-
es have receptors for both dominating adipokines: lep-
tin and adiponectin [15].
Adiponectin induces apoptosis of monocytes and
inhibits the process of phagocytosis by macrophages.
Leptin acts in the opposite way: it increases prolifera-
tion and migration of monocytes and stimulates phago-
cytosis. Thus, the inflammatory reaction may be sup-
ported by abnormal auto- and paracrine activity of ad-
ipose tissue. Subclinical inflammation probably plays
the most important role in the development of insulin
resistance and type 2 diabetes in obese patients [16]. The
leptin-adiponectin ratio is regarded as a potential
atherogenic index in obese patients [55].
Conclusions
1. The results show the significant role of non-phar-
macological procedure in obesity treatment and the
positive results of introducing the treatment as ear-
ly as possible. The earlier the implementation of
a LC diet, the better the chances for regression of
the metabolic disturbances.
2. One of the mechanisms through which a low-calo-
rie diet may limit the development of the inflamma-
tory process related to obesity could be the decrease
in leptin concentration.
3. The decrease in adiponectin concentration, which
is proportional to the level of insulin resistance and
obesity, may be one of the causes of pro-inflamma-
tory and pro-coagulation trends in overweight and
obese people.
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